KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Investing Activities (2020 - 2026)

AbCellera Biologics filings provide 7 years of Cash from Investing Activities readings, the most recent being -$25.1 million for Q1 2026.

  • Quarterly Cash from Investing Activities fell 416.08% to -$25.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $54.7 million through Mar 2026, down 44.95% year-over-year, with the annual reading at $87.8 million for FY2025, 27.72% down from the prior year.
  • Cash from Investing Activities hit -$25.1 million in Q1 2026 for AbCellera Biologics, down from $75.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $75.1 million in Q4 2025 and bottomed at -$282.0 million in Q3 2022.
  • Average Cash from Investing Activities over 5 years is -$22.9 million, with a median of -$17.1 million recorded in 2022.
  • The largest annual shift saw Cash from Investing Activities tumbled 1385.03% in 2022 before it skyrocketed 886.7% in 2025.
  • AbCellera Biologics' Cash from Investing Activities stood at -$17.1 million in 2022, then crashed by 42.55% to -$24.3 million in 2023, then skyrocketed by 246.79% to $35.7 million in 2024, then surged by 110.45% to $75.1 million in 2025, then plummeted by 133.38% to -$25.1 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Cash from Investing Activities are -$25.1 million (Q1 2026), $75.1 million (Q4 2025), and $36.5 million (Q3 2025).